Amicus Therapeutics Inc. Stock
Amicus Therapeutics Inc. Stock
Amicus Therapeutics Inc. dominated the market today, gaining €2.80 (30.430%).
With 6 Buy predictions and not the single Sell prediction the community is currently very high on Amicus Therapeutics Inc..
As a result the target price of 16 € shows a positive potential of 33.33% compared to the current price of 12.0 € for Amicus Therapeutics Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Amicus Therapeutics Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Amicus Therapeutics Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
B****
Cons
?
S********** s********
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Amicus Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Amicus Therapeutics Inc. | 30.430% | 1.099% | 13.580% | -1.075% | 0.546% | -17.087% | -54.000% |
| Repligen Corp. | -1.530% | 2.541% | 0.106% | 0.929% | 0.929% | -10.397% | -12.485% |
| Opko Health Inc. | -1.850% | 2.406% | -0.638% | -21.687% | -21.541% | 4.327% | -70.394% |
| Hutchison China Meditech Ltd | 0.000% | 0.000% | -9.402% | -18.462% | -17.829% | -20.896% | -53.712% |
Comments
Amicus Therapeutics (NASDAQ:FOLD) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $17.00 price target on the stock.
Show more
Ratings data for FOLD provided by MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) had its price target raised by analysts at JPMorgan Chase & Co. from $18.00 to $19.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for FOLD provided by MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.
Show more
Ratings data for FOLD provided by MarketBeat
News
Amicus (FOLD) Q2 Revenue Jumps 22%
Amicus Therapeutics (NASDAQ:FOLD), a specialist in rare disease medicines, delivered quarterly results on July 31, 2025 that notably surpassed expectations on both GAAP revenue and non-GAAP
